PCSK9 and familial hypercholesterolemia: Inclisiran requires less frequency than monoclonal antibody regimen administration and has similar safety and efficiency in reducing LDL-C and PCSK9 levels, as shown in studies for both primary and secondary prevention and familial hypercholesterolemia [115,116].